TRITON-TIMI 38 and PLATO trials showed that potent P2Y12 inhibitors, including prasugrel and ticagrelor, were superior to clopidogrel for the reduction of ischemic events in acute coronary syndrome patients [3,4]. The gene discussed is P2RY12; the disease is acute coronary syndrome.